SLC5A2 and type 2 diabetes mellitus: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have recently gained scientific interest due to their well-established cardioprotective profile among patients with type 2 diabetes (T2DM).19,20 Several possible mechanisms were established to explain the cardioprotective effects of SGLT2i.